Cited by 998Schizophrenia research and treatmentNeurotransmitter Receptor Influence on BehaviorTreatment of Major Depression

The DOI matches its Crossref record; 390 of the 393 references it cites were found in a registry or an index.

Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs

Miyamoto, S, Duncan, G E, Marx, C E, Lieberman, J A·2005·Molecular Psychiatry

DOI 10.1038/sj.mp.4001556

Open this paper in CoChat — free account

Abstract

The treatment of schizophrenia has evolved over the past half century primarily in the context of antipsychotic drug development. Although there has been significant progress resulting in the availability and use of numerous medications, these reflect three basic classes of medications (conventional (typical), atypical and dopamine partial agonist antipsychotics) all of which, despite working by varying mechanisms of actions, act principally on dopamine systems. Many of the second-generation (atypical and dopamine partial agonist) antipsychotics are believed to offer advantages over first-generation agents in the treatment for schizophrenia. However, the pharmacological properties that confer the different therapeutic effects of the new generation of antipsychotic drugs have remained elusive, and certain side effects can still impact patient health and quality of life. Moreover, the efficacy of antipsychotic drugs is limited prompting the clinical use of adjunctive pharmacy to augment the effects of treatment. In addition, the search for novel and nondopaminergic antipsychotic drugs has not been successful to date, though numerous development strategies continue to be pursued, guided by various pathophysiologic hypotheses. This article provides a brief review and critique of the current therapeutic armamentarium for treating schizophrenia and drug development strategies and theories of mechanisms of action of antipsychotics, and focuses on novel targets for therapeutic agents for future drug development.

Integrity signals

Registry

Crossref · 10.1038/sj.mp.4001556

Cites

390 of 390 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Glutamate uptake
Danbolt, N. C. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00067-8 · Cited by 4,227
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
Implications of Normal Brain Development for the Pathogenesis of Schizophrenia
Weinberger, D. R. (1987) · Archives of General Psychiatry · doi:10.1001/archpsyc.1987.01800190080012 · Cited by 3,724
Subanesthetic Effects of the Noncompetitive NMDA Antagonist, Ketamine, in Humans: Psychotomimetic, Perceptual, Cognitive, and Neuroendocrine Responses
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
Effect of COMT Val 108/158 Met genotype on frontal lobe function and risk for schizophrenia
Egan, M. F., Goldberg, T. E., Kolachana, B. S., Callicott, J. H., Mazzanti, C. M., Straub, R. E., Goldman, D. A., & Weinberger, D. R. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.111134598 · Cited by 2,416
Antipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382
Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs
Creese, I., Burt, D. R., & Snyder, S. H. (1976) · Science · doi:10.1126/science.3854 · Cited by 2,220
Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine
Tol, H. H. M. V., Bunzow, J. R., Guan, H., Sunahara, R. K., Seeman, P. M., Niznik, H. B., & Civelli, O. (1991) · Nature · doi:10.1038/350610a0 · Cited by 2,015
Activation of Glutamatergic Neurotransmission by Ketamine: A Novel Step in the Pathway from NMDA Receptor Blockade to Dopaminergic and Cognitive Disruptions Associated with the Prefrontal Cortex
Moghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793

Flagged first, then by citations

Show all 393 references

3 of the 393 references couldn’t be matched to a known paper.

Research works printed but not linked: 15

Breier A, Wright P, Birkett M, Meehan K, David, Brook S . A double-blind dose response study comparing intramuscular olanzapine, haloperidol and placebo in acutely agitated schizophrenic patients, ACNP 39th Annual Meeting Abstract. American College of Neuropsychopharmacology: Puerto Rico, 2000.
Waddington J, Casey D . Comparative pharmacology of classical and novel (second-generation) antipsychotics. In: Buckley PF, Waddington JL (eds). Schizophrenia and Mood Disorders: The New Drug Therapies in Clinical Practice. Butterworth-Heinemann: Woburn, MA, 2000, pp 3–13.
Carlsson A . Focusing on dopaminergic stabilizers and 5-HT2A receptor antagonists. Curr Opin CPNS Invest Drugs 2000; 2: 22–24.
Patel JK, Pinals DA, Breier A . Schizophrenia and other psychoses. In: Tasman A, Kay J, Lieberman JA (eds). PSYCHIATRY, 2nd edn. John Wiley & Sons, Ltd: Chichester, 2003, pp 1131–1206.
Ferris P . Ziprasidone. Curr Opin CPNS Invest Drugs 2000; 2: 58–70.
Nichols DE, Mailman RB . Substituted hexa-hydro[a]phenanthridines. US Patent 1995; 5: 134.
Nichols DE, Mailman RB . Fused isoquinolines as dopamine receptor ligands. US Patent 1999; 5: 110.
Danysz W . Sonepiprazole. Curr Opin CPNS Invest Drugs 2000; 2: 97–104.
Mansbach RS, Brooks EW, Sanner MA, Zorn SH . Selective dopamine D4 receptor antagonists reverse apomorphine-induced blockade of prepulse inhibition. Psychopharmacology 1998; 135: 194–200. · DOI
Abi-Saab WM, D'Souza DC, Madonick SH, Krystal JH . Targeting the glutamate system. In: Breier A, Tran PV, Herrera JM, Tollefson GD, Bymaster FP (eds). Current Issues in the Psychopharmacology of Schizophrenia. Lippincott Williams & Wilkins Healthcare, Philadelphia, 2001, pp 304–332.
Goff D, Berman I, Posever T, Leahy L, Lynch G . A preliminary dose-escalation trial of CX 516 (ampakine) added to clozapine in schizophrenia. Schizophr Res 1999; 36: 280.
Bymaster FP . Possible role of muscarinic receptor agonists as therapeutic agents for psychosis. In: Breier A, Tran PV, Herrera JM, Tollefson GD, Bymaster FP (eds). Current Issues in the Psychopharmacology of Schizophrenia. Lippincott Williams & Wilkins Healthcare, Philadelphia, 2001, pp 333–348.
Perry KW, Bymaster FP, Shannon HE, Rasmussen K, DeLapp NW, Zhang W et al. The muscarinic agonist xanomeline has antipsychotic-like activity in animals and in man. Schizophr Res 1999; 36: 117–118.
Basile VS, Masellis M, Ozdemir V, Meltzer HY, Macciardi FM, Kennedy JL . Application of pharmacogenetics to schizophrenia: Emerging insights from studies of clozapine response and tardive dyskinesia. In: Breier A, Tran PV, Herrera JM, Tollefson GD, Bymaster FP (eds). Current Issues in the Psychopharmacology of Schizophrenia. Lippincott Williams & Wilkins Healthcare, Philadelphia, 2001, pp 85–110.
Stroup TS, McEvoy JP, Swartz MS, Byerly MJ, Glick ID, Canive JM et al. The National Institute of Mental Health Clinical Antipsychotic Trials in Intervention Effectiveness (CATIE) Project: Schizophrenia trial design and protocol development. Schizophrenia Bull 2003; 29: 15–31. · DOI

Sorted by citations

Items 101–200 of 998

Dopamine D2 and 5-hydroxytryptamine 5-HT2A receptors assemble into functionally interacting heteromers
Borroto‐Escuela, D. O., Romero‐Fernandez, W., Tarakanov, A. O., Marcellino, D. J., Ciruela, F., Agnati, L. F., & Fuxé, K. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.09.110 · Cited by 98
Atypical antipsychotics in the management of delirium: A review of the empirical literature
Böettger, S., & BREITBART, W. S. (2005) · Palliative & Supportive Care · doi:10.1017/s1478951505050352 · Cited by 96
Clozapine versus other atypical antipsychotics for schizophrenia
Lobos, C. A., Komossa, K., Rummel‐Kluge, C., Hunger, H., Schmid, F., Schwarz, S., & Leucht, S. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006633 · Cited by 95
Epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs
Tarsy, D., Lungu, C., & Baldessarini, R. J. (2011) · Handbook of clinical neurology · doi:10.1016/b978-0-444-52014-2.00043-4 · Cited by 95
The Alkaloid Alstonine: A Review of Its Pharmacological Properties
Elisabetsky, E., & Costa-Campos, L. (2006) · Evidence-based Complementary and Alternative Medicine · doi:10.1093/ecam/nek011 · Cited by 97
Antipsychotic-Induced Metabolic and Cardiovascular Side Effects in Schizophrenia: A Novel Mechanistic Hypothesis
Scigliano, G., & Ronchetti, G. (2013) · CNS Drugs · doi:10.1007/s40263-013-0054-1 · Cited by 92
Cognition in transmembrane domain neuregulin 1 mutant mice
Duffy, L., Cappas, E., Lai, D., Boucher, A. A., & Karl, T. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.07.042 · Cited by 95
GLT-1 transporter: An effective pharmacological target for various neurological disorders
Soni, N., Reddy, B. V. K., & Kumar, P. (2014) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2014.10.001 · Cited by 99
Does the dopamine hypothesis explain schizophrenia?
Lau, C. I., Wang, H.-C., Hsu, J.-L., & Liu, M. (2013) · Reviews in the Neurosciences · doi:10.1515/revneuro-2013-0011 · Cited by 102
Non-invasive intranasal delivery of quetiapine fumarate loaded microemulsion for brain targeting: Formulation, physicochemical and pharmacokinetic consideration
Shah, B. M., Khunt, D., Misra, M., & Padh, H. (2016) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2016.05.008 · Cited by 93
The muscarinic system, cognition and schizophrenia
Carruthers, S. P., Gurvich, C. T., & Rossell, S. L. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.05.011 · Cited by 90
Cannabidiol exhibits anxiolytic but not antipsychotic property evaluated in the social interaction test
de Almeida, V., Levin, R. R., Peres, F. F., Niigaki, S. T., Calzavara, M. B., Zuardi, A. W., Hallak, J. E. C., Crippa, J. A. S., & Abílio, V. C. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.10.024 · Cited by 93
Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia
Fell, M. J., McKinzie, D. L., Monn, J. A., & Svensson, K. A. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.06.007 · Cited by 90
Drug-induced activation of SREBP-controlled lipogenic gene expression in CNS-related cell lines: Marked differences between various antipsychotic drugs
Fernø, J., Skrede, S., Vik‐Mo, A. O., Håvik, B., & Steen, V. M. (2006) · BMC Neuroscience · doi:10.1186/1471-2202-7-69 · Cited by 91
Comparative Effectiveness of Antipsychotic Drugs
Lieberman, J. A. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.10.1069 · Cited by 88
Self-citation
Adverse effects of antipsychotics on micro-vascular endothelial cells of the human blood–brain barrier
Elmorsy, E. M., El-Zalabany, L., Elsheikha, H. M., & Smith, P. A. (2014) · Brain Research · doi:10.1016/j.brainres.2014.08.011 · Cited by 88
Clozapine's Multiple Cellular Mechanisms: What Do We Know after More than Fifty Years? a Systematic Review and Critical Assessment of Translational Mechanisms Relevant for Innovative Strategies in Treatment-Resistant Schizophrenia
de Bartolomeis, A., Vellucci, L., Barone, A., Manchia, M., Luca, V. D., Iasevoli, F., & Correll, C. U. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108236 · Cited by 96
Hallucinogenic 5-HT2AR agonists LSD and DOI enhance dopamine D2R protomer recognition and signaling of D2-5-HT2A heteroreceptor complexes
Borroto‐Escuela, D. O., Romero‐Fernandez, W., Narváez, M., Oflijan, J., Agnati, L. F., & Fuxé, K. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.11.104 · Cited by 88
Anti-inflammatory Strategies for Schizophrenia: A Review of Evidence for Therapeutic Applications and Drug Repurposing
Hong, J., & Bang, M. (2020) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2020.18.1.10 · Cited by 90
Targeting muscarinic receptors to treat schizophrenia
Foster, D. J., Bryant, Z., & Conn, P. J. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2021.113201 · Cited by 92
Building a Better Antipsychotic: Receptor Targets for the Treatment of Multiple Symptom Dimensions of Schizophrenia
Kim, D. H., Maneen, M. J., & Stahl, S. M. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.10.020 · Cited by 87
Alzheimer's disease and age-related memory decline (preclinical)
Terry, A. V., Callahan, P. M., Hall, B. J., & Webster, S. J. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.02.002 · Cited by 86
The association between weight change and symptom reduction in the CATIE schizophrenia trial
Hermes, E. D. A., Nasrallah, H. A., Davis, V. G., Meyer, J. M., McEvoy, J. P., GOFF, D. C., Thomas, S., Stroup, T. S., Swartz, M. S., Lieberman, J. A., et al. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.01.022 · Cited by 87
Self-citation
Dysregulated 5-HT2A receptor binding in postmortem frontal cortex of schizophrenic subjects
Muguruza, C., Moreno, J. L., Umali, A., Callado, L. F., Meana, J. J., & González‐Maeso, J. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.10.006 · Cited by 86
Antipsychotic use and the risk of hip/femur fracture: a population-based case–control study
Pouwels, S., van Staa, T. P., Egberts, T. C. G., Leufkens, H. G. M., Cooper, C. C., & de Vries, F. (2009) · Osteoporosis International · doi:10.1007/s00198-008-0826-5 · Cited by 87
DNA methylation and antipsychotic treatment mechanisms in schizophrenia: Progress and future directions
Ovenden, E. S., McGregor, N. W., Emsley, R. A., & Warnich, L. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.10.004 · Cited by 88
Modeling psychiatric disorders with patient-derived iPSCs
Wen, Z., Christian, K. M., Song, H., & Ming, G.-L. (2016) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2015.11.003 · Cited by 84
Alterations of dopamine and serotonin transmission in schizophrenia
Remington, G. (2008) · Progress in brain research · doi:10.1016/s0079-6123(08)00906-0 · Cited by 83
The heterogeneity of antipsychotic response in the treatment of schizophrenia
Case, M., Stauffer, V. L., Ascher‐Svanum, H., Conley, R. R., Kapur, S., Kane, J. M., Kollack‐Walker, S., Jacob, J., & Kinon, B. J. (2010) · Psychological Medicine · doi:10.1017/s0033291710001893 · Cited by 85
Clozapine, atypical antipsychotics, and the benefits of fast-off D2 dopamine receptor antagonism
Vauquelin, G., Bostoen, S., Vanderheyden, P., & Seeman, P. M. (2012) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-012-0734-2 · Cited by 80
A reversible model of the cognitive impairment associated with schizophrenia in monkeys: Potential therapeutic effects of two nicotinic acetylcholine receptor agonists
Buccafusco, J. J., & Terry, A. V. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.06.102 · Cited by 79
Dopamine, the antipsychotic molecule: A perspective on mechanisms underlying antipsychotic response variability
Amato, D., Vernon, A. C., & Papaleo, F. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.09.027 · Cited by 81
Aripiprazole: from pharmacological profile to clinical use
Riva, M. A., & Sciascio, G. D. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s88117 · Cited by 86
Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making
Volavka, J., & Citrome, L. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903061309 · Cited by 78
Animal models of eating disorders
Kim, S. F. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.03.024 · Cited by 86
Metformin and Berberine Prevent Olanzapine-Induced Weight Gain in Rats
Hu, Y., Young, A. J., Ehli, E. A., Nowotny, D., Davies, P. S., Droke, E. A., Soundy, T. J., & Davies, G. E. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093310 · Cited by 76
Discovery of 4-(5-Methyloxazolo[4,5- b ]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (CP-810,123), a Novel α7 Nicotinic Acetylcholine Receptor Agonist for the Treatment of Cognitive Disorders in Schizophrenia: Synthesis, SAR Development, and in Vivo Efficacy in Cognition Models
O’Donnell, C. J., Rogers, B. N., Bronk, B. S., Bryce, D. K., Coe, J. W., Cook, K. K., Duplantier, A. J., Evrard, E., Hajós, M., Hoffmann, W. E., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm9015075 · Cited by 75
Antipsychotic drug actions on gene modulation and signaling mechanisms
Molteni, R., Calabrese, F., Racagni, G., Fumagalli, F., & Riva, M. A. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.06.001 · Cited by 78
The past and future of novel, non-dopamine-2 receptor therapeutics for schizophrenia: A critical and comprehensive review
Girgis, R. R., Zoghbi, A. W., Javitt, D. C., & Lieberman, J. A. (2018) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2018.07.006 · Cited by 75
Self-citation
Age-dependent regulation of synaptic connections by dopamine D2 receptors
Jia, J., Zhao, J. W., Hu, Z., Lindberg, D. M., & Li, Z. (2013) · Nature Neuroscience · doi:10.1038/nn.3542 · Cited by 72
Chronic neuroleptic treatment reduces endogenous kynurenic acid levels in rat brain
Ceresoli‐Borroni, G., Rassoulpour, A., Wu, H., Guidetti, P., & Schwarcz, R. M. (2006) · Journal of Neural Transmission · doi:10.1007/s00702-005-0432-z · Cited by 72
The natural hallucinogen 5-MeO-DMT, component of Ayahuasca, disrupts cortical function in rats: reversal by antipsychotic drugs
Riga, M. S., Sòria, G., Tudela, R., Artigas, F., & Celada, P. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145714000261 · Cited by 76
Ulotaront: A TAAR1 Agonist for the Treatment of Schizophrenia
Heffernan, M. L. R., Herman, L. W., Brown, S. P., JONES, P. G., Shao, L., Hewitt, M. C., Campbell, J. E., Dedic, N., Hopkins, S. C., Koblan, K. S., et al. (2021) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.1c00527 · Cited by 71
GSK-3β activity and hyperdopamine-dependent behaviors
Li, Y., & Gao, W. (2010) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.08.001 · Cited by 72
Spontaneously Hypertensive Rats (SHR) present deficits in prepulse inhibition of startle specifically reverted by clozapine
Levin, R. R., Calzavara, M. B., Santos, C. M., Medrano, W. A., Niigaki, S. T., & Abílio, V. C. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2011.06.003 · Cited by 71
Perspectives on the mGluR2/3 agonists as a therapeutic target for schizophrenia: Still promising or a dead end?
Li, M.-L., Hu, X., Li, F., & Gao, W. (2015) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.02.012 · Cited by 71
Constitutive Activation of Gαs within Forebrain Neurons Causes Deficits in Sensorimotor Gating Because of PKA-Dependent Decreases in cAMP
Kelly, M. P., Isiegas, C., Cheung, Y.-F., Tokarczyk, J., Yang, X., Esposito, M. F., Rapoport, D. A., Fabian, S., Siegel, S. J., Wand, G. S., et al. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301099 · Cited by 72
Intrinsic Connectivity Patterns of Task-Defined Brain Networks Allow Individual Prediction of Cognitive Symptom Dimension of Schizophrenia and Are Linked to Molecular Architecture
Ji, C., Müller, V. I., Dukart, J., Hoffstaedter, F., Baker, J. T., Holmes, A. J., Vatansever, D., Nickl‐Jockschat, T., Liu, X., Derntl, B., et al. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2020.09.024 · Cited by 67
Genome-wide association study of antipsychotic-induced parkinsonism severity among schizophrenia patients
Alkelai, A., Greenbaum, L., Rigbi, A., Kanyas, K., & Lerer, B. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1627-z · Cited by 70
Oral haloperidol or risperidone treatment in rats: Temporal effects on nerve growth factor receptors, cholinergic neurons, and memory performance
Terry, A. V., Gearhart, D. A., Warner, S., Zhang, G., Bartlett, M. G., Middlemore, M.-L., Beck, W. D., Mahadik, S. P., & Waller, J. L. (2007) · Neuroscience · doi:10.1016/j.neuroscience.2007.03.003 · Cited by 70
Changes in Brain Glutamate on Switching to Clozapine in Treatment-Resistant Schizophrenia
McQueen, G., Sendt, K.-V., Gillespie, A. L., Avila, A., Lally, J., Vallianatou, K., Chang, N., Ferreira, D., Borgan, F., Howes, O. D., et al. (2020) · Schizophrenia Bulletin · doi:10.1093/schbul/sbaa156 · Cited by 74
Lipid peroxidation in patients with schizophrenia
Dietrich‐Muszalska, A., & Kontek, B. (2010) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2010.02132.x · Cited by 69
Vitamin Supplementation in the Treatment of Schizophrenia
Brown, H. E., & Roffman, J. L. (2014) · CNS Drugs · doi:10.1007/s40263-014-0172-4 · Cited by 69
Association of a Schizophrenia Risk Variant at theDRD2Locus With Antipsychotic Treatment Response in First-Episode Psychosis
Zhang, J., Robinson, D. G., Gallego, J. A., John, M., Yu, J., Addington, J., Tohen, M. F., Kane, J. M., Malhotra, A. K., & Lencz, T. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbv116 · Cited by 69
Impact of species variability and ‘probe‐dependence’ on the detection andin vivovalidation of allosteric modulation at the M4muscarinic acetylcholine receptor
Suratman, S., Leach, K., Sexton, P. M., Felder, C. C., Loiacono, R. E., & Christopoulos, A. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01184.x · Cited by 68
Role of 5-HT receptor mechanisms in sub-chronic PCP-induced reversal learning deficits in the rat
McLean, S. L., Woolley, M. L., Thomas, D. W., & Neill, J. C. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1618-0 · Cited by 68
Emerging drugs for schizophrenia
Agid, O., Kapur, S., & Remington, G. J. (2008) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.13.3.479 · Cited by 68
The anti-psychotic drug pimozide is a novel chemotherapeutic for breast cancer
Dakir, E. H., Pickard, A., Srivastava, K., McCrudden, C. M., Gross, S. R., Lloyd, S., Zhang, S., Margariti, A., Morgan, R., Rudland, P. S., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.26175 · Cited by 68
The experiences of providing caregiving for patients with schizophrenia in the Ghanaian context
Gloria, O., Osafo, J., Goldmann, E., Parikh, N. S., Nonvignon, J., & Kretchy, I. A. (2018) · Archives of Psychiatric Nursing · doi:10.1016/j.apnu.2018.06.005 · Cited by 66
Genetic variation in BDNF is associated with antipsychotic treatment resistance in patients with schizophrenia
Zhang, J., Lencz, T., Geisler, S., DeRosse, P., Bromet, E. J., & Malhotra, A. K. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.01.020 · Cited by 68
The role of dopamine D 3 receptors in the mechanism of action of cariprazine
Calabrese, F., Tarazi, F. I., Racagni, G., & Riva, M. A. (2019) · CNS Spectrums · doi:10.1017/s109285291900083x · Cited by 66
Discovery and Optimization of a Series of Pyrimidine-Based Phosphodiesterase 10A (PDE10A) Inhibitors through Fragment Screening, Structure-Based Design, and Parallel Synthesis
Shipe, W. D., Sharik, S. S., Barrow, J. C., McGaughey, G. B., Theberge, C. R., Uslaner, J. M., Yan, Y., Renger, J. J., Smith, S. M., Coleman, P. J., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00983 · Cited by 65
Surface-enhanced Raman scattering for dopamine in Ag colloid: Adsorption mechanism and detection in the presence of interfering species
Figueiredo, M. L. B., Martin, C. S., Furini, L. N., Rubira, R. J. G., Batagin‐Neto, A., Aléssio, P., & Constantino, C. J. L. (2020) · Applied Surface Science · doi:10.1016/j.apsusc.2020.146466 · Cited by 65
Inhibition of glycogen synthase kinase 3 by lithium, a mechanism in search of specificity
Chatterjee, D., & Beaulieu, J. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.1028963 · Cited by 65
Developmental etiology for neuroanatomical and cognitive deficits in mice overexpressing Gαs, a G-protein subunit genetically linked to schizophrenia
Kelly, M. P., Stein, J. M., Vecsey, C. G., Favilla, C. G., Yang, X., Bizily, S. P., Esposito, M., Wand, G. S., Kanes, S., & Abel, T. G. (2008) · Molecular Psychiatry · doi:10.1038/mp.2008.124 · Cited by 65
Time-Dependent Cognitive Deficits Associated with First and Second Generation Antipsychotics: Cholinergic Dysregulation as a Potential Mechanism
Terry, A. V., & Mahadik, S. P. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.106047 · Cited by 63
Antipsychotic use in pregnancy
Kulkarni, J., Storch, A., Baraniuk, A., Gilbert, H., Gavrilidis, E., & Worsley, R. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1041501 · Cited by 63
Risperidone modulates the cytokine and chemokine release of dendritic cells and induces TNF-α-directed cell apoptosis in neutrophils
Chen, M., Tsai, T., Wang, L., Lin, Y.-Y., Tsai, Y.-M., Lee, M.-C., & Tsai, F. (2011) · International Immunopharmacology · doi:10.1016/j.intimp.2011.11.011 · Cited by 64
Aripiprazole inhibits superoxide generation from phorbol-myristate-acetate (PMA)-stimulated microglia in vitro: Implication for antioxidative psychotropic actions via microglia
Kato, T. A., Monji, A., Yasukawa, K., Mizoguchi, Y., Horikawa, H., Seki, Y., Hashioka, S., Han, Y.-H., Kasai, M., Sonoda, N., et al. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.03.019 · Cited by 63
Effects of antipsychotics and amphetamine on social behaviors in spontaneously hypertensive rats
Calzavara, M. B., Levin, R. R., Medrano, W. A., de Almeida, V., Sampaio, A. P. F., Barone, L. C., Frussa‐Filho, R., & Abílio, V. C. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.06.026 · Cited by 62
Antipsychotics inhibit TREK but not TRAAK channels
Thümmler, S., Duprat, F., & Lazdunski, M. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.12.199 · Cited by 67
Genome-wide Mendelian randomization identifies actionable novel drug targets for psychiatric disorders
Liu, J., Cheng, Y., Li, M., Zhang, Z., Li, T., & Luo, X. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01456-5 · Cited by 60
Mice Lacking the Immediate Early Gene Egr3 Respond to the Anti-Aggressive Effects of Clozapine Yet are Relatively Resistant to its Sedating Effects
Gallitano, A. L., Wozniak, D. F., Pehek, E. A., & Milbrandt, J. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301505 · Cited by 61
Group II metabotropic glutamate receptors and schizophrenia
Moreno, J. L., Sealfon, S. C., & González‐Maeso, J. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-0130-3 · Cited by 61
Contributing factors to weight gain during long‐term treatment with second‐generation antipsychotics. A systematic appraisal and clinical implications
Gentile, S. (2009) · Obesity Reviews · doi:10.1111/j.1467-789x.2009.00589.x · Cited by 61
Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia
Earley, W. R., Durgam, S., Lu, K., Laszlovszky, I., Debelle, M., & Kane, J. M. (2017) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000187 · Cited by 61
Do Antipsychotics Improve Reasoning Biases? A Review
So, S., Garety, P., Peters, E., & Kapur, S. (2010) · Psychosomatic Medicine · doi:10.1097/psy.0b013e3181e7cca6 · Cited by 75
The M1/M4 preferring agonist xanomeline reverses amphetamine-, MK801- and scopolamine-induced abnormalities of latent inhibition: putative efficacy against positive, negative and cognitive symptoms in schizophrenia
Barak, S., & Weiner, I. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710001549 · Cited by 60
Formulation and biopharmaceutical evaluation of risperidone-loaded chitosan nanoparticles for intranasal delivery
Rukmangathen, R., Muzib, Y. I., & Yalavarthi, P. R. (2019) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2019.1619759 · Cited by 61
Neurodevelopmental Animal Models Reveal the Convergent Role of Neurotransmitter Systems, Inflammation, and Oxidative Stress as Biomarkers of Schizophrenia: Implications for Novel Drug Development
Möller, M., Swanepoel, T., & Harvey, B. H. (2015) · ACS Chemical Neuroscience · doi:10.1021/cn5003368 · Cited by 60
An open trial of aripiprazole for the treatment of delirium in hospitalized cancer patients
Böettger, S., & BREITBART, W. S. (2011) · Palliative & Supportive Care · doi:10.1017/s1478951511000368 · Cited by 59
A Cell-Based Ultra-High-Throughput Screening Assay for Identifying Inhibitors of D-Amino Acid Oxidase
Brandish, P. E., Chiu, C., Schneeweis, J. E., Brandon, N. J., Leech, C. L., Kornienko, O., Scolnick, E. M., Strulovici, B., & Zheng, W. (2006) · SLAS DISCOVERY · doi:10.1177/1087057106288181 · Cited by 59
A phase 2, randomized, placebo-controlled study of the efficacy and safety of TAK-063 in subjects with an acute exacerbation of schizophrenia
Macek, T. A., McCue, M., Dong, X., Hanson, E., Goldsmith, P., Affinito, J., & Mahableshwarkar, A. R. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2018.08.028 · Cited by 59
Excitatory and inhibitory synaptic dysfunction in mania: an emerging hypothesis from animal model studies
Lee, Y., Zhang, Y., Kim, S., & Han, K. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0028-y · Cited by 60
Animal models for predicting the efficacy and side effects of antipsychotic drugs.
Gobira, P., Ropke, J., Aguiar, D., Crippa, J., & Moreira, F. (2013) · Revista Brasileira de Psiquiatria · doi:10.1590/1516-4446-2013-1164 · Cited by 56
Inducible ablation of dopamine D2 receptors in adult mice impairs locomotion, motor skill learning and leads to severe parkinsonism
Bello, E. P., Casas-Cordero, R., Galiñanes, G. L., Casey, E., Belluscio, M., Rodríguez, V., Noaín, D., Murer, M. G., & Rubinstein, M. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.105 · Cited by 57
Oral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitation
Villari, V., Rocca, P., Fonzo, V., Montemagni, C., Pandullo, P., & Bogetto, F. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.09.007 · Cited by 58
Pro-Cognitive and Antipsychotic Efficacy of the α7 Nicotinic Partial Agonist SSR180711 in Pharmacological and Neurodevelopmental Latent Inhibition Models of Schizophrenia
Barak, S., Arad, M., Levie, A. D., Black, M. D., Griebel, G., & Weiner, I. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.232 · Cited by 57
The Isoxazole Ring and Its N‐Oxide: A Privileged Core Structure in Neuropsychiatric Therapeutics
Pairas, G., Perperopoulou, F., Tsoungas, P. G., & Varvounis, G. (2017) · ChemMedChem · doi:10.1002/cmdc.201700023 · Cited by 57
Haloperidol and Clozapine Differentially Affect the Expression of Arrestins, Receptor Kinases, and Extracellular Signal-Regulated Kinase Activation
Ahmed, M. R., Gurevich, V. V., Dalby, K. N., Benovic, J., & Gurevich, E. V. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.131987 · Cited by 57
The modulation of adult neuroplasticity is involved in the mood-improving actions of atypical antipsychotics in an animal model of depression
Morais, M., Patrício, P., Mateus-Pinheiro, A., Alves, N. D., Machado-Santos, A. R., Correia, J. S., Pereira, J., Pinto, L., Sousa, N., & Bessa, J. M. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.120 · Cited by 56
Clinical Pharmacology of Dopamine-Modulating Agents in Tourette’s Syndrome
Mogwitz, S., Buse, J., Ehrlich, S., & Roessner, V. (2013) · International review of neurobiology · doi:10.1016/b978-0-12-411546-0.00010-x · Cited by 57
In Silico Receptorome Screening of Antipsychotic Drugs
Vidal, D., & Mestres, J. (2010) · Molecular Informatics · doi:10.1002/minf.201000055 · Cited by 58
Diversity and Bias through Receptor–Receptor Interactions in GPCR Heteroreceptor Complexes. Focus on Examples from Dopamine D2 Receptor Heteromerization
Fuxé, K., Tarakanov, A. O., Romero‐Fernandez, W., Ferraro, L., Tanganelli, S., Filip, M., Agnati, L. F., Garriga, P., Dı́az-Cabiale, Z., & Borroto‐Escuela, D. O. (2014) · Frontiers in Endocrinology · doi:10.3389/fendo.2014.00071 · Cited by 57
Evaluation of Five Antischizophrenic Agents Against Toxoplasma gondii in Human Cell Cultures
Goodwin, D. G., Strobl, J. S., & Lindsay, D. S. (2011) · Journal of Parasitology · doi:10.1645/ge-2536.1 · Cited by 55
Atypical antipsychotics and inverse agonism at 5-HT2 receptors
Sullivan, L. C., Clarke, W. P., & Berg, K. A. (2015) · Current Pharmaceutical Design · doi:10.2174/1381612821666150605111236 · Cited by 56
A dimensional approach to modeling symptoms of neuropsychiatric disorders in the marmoset monkey
Oikonomidis, L., Santangelo, A. M., Shiba, Y., Clarke, F. H., Robbins, T. W., & Roberts, A. C. (2017) · Developmental Neurobiology · doi:10.1002/dneu.22446 · Cited by 54
Lack of BDNF expression through promoter IV disturbs expression of monoamine genes in the frontal cortex and hippocampus
Sakata, K., & Duke, S. M. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.12.013 · Cited by 54
Molecular properties affecting fast dissociation from the D2 receptor
Tresadern, G., Bartolomé, J. M., Macdonald, G. J., & Langlois, X. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.02.033 · Cited by 56
Olanzapine, but not clozapine, increases glutamate release in the prefrontal cortex of freely moving mice by inhibiting D-aspartate oxidase activity
Sacchi, S., de Novellis, V., Paolone, G., Nuzzo, T., Iannotta, M., Belardo, C., Squillace, M., Bolognesi, P., Rosini, E., Motta, Z., et al. (2017) · Scientific Reports · doi:10.1038/srep46288 · Cited by 54

Authors: Miyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A.
Affiliations: St. Marianna University School of Medicine (JP)
University of North Carolina at Chapel Hill (US)
Duke Medical Center (US)
Corresponding author: Lieberman, J A
Venue: Molecular Psychiatry
Publisher: Springer Science and Business Media LLC
Published: 2004-08-03
Volume: 10
Issue: 1
Pages: 79-104
ISSN: 1359-4184 (ISSN-L)
1476-5578
DOI: 10.1038/sj.mp.4001556
OpenAlex: W2132980997
Cited by: 988
References: 393
Citations by year: 2026: 23 · 2025: 25 · 2024: 32 · 2023: 40 · 2022: 37 · 2021: 40 · 2020: 45 · 2019: 42 · 2018: 40 · 2017: 41 · 2016: 54 · 2015: 52 · 2014: 46 · 2013: 72 · 2012: 66
FWCI: 4.72
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Molecular Psychiatry (publishedVersion)
PubMed (publishedVersion)
Funders: National Institute of Mental Health (MH064065, P50MH064065)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Keywords: schizophrenia, antipsychotic drugs, dopamine D2 receptor, atypical antipsychotics, partial dopamine agonist, typical antipsychotics, mechanism of action, antipsychotic adverse effects, adjunctive pharmacotherapy, antipsychotic drug development, schizophrenia pathophysiology
MeSH terms: Behavioral Symptoms, Humans, Schizophrenia, Antipsychotic Agents, Drug Design, Dopamine Agents, Receptors, Dopamine D2, Receptors, Glutamate, Excitatory Amino Acid Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks